Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.

3543

Cantargia is a Swedish biotechnology company focused on developing new concepts for immunotherapeutic treatment of cancer and autoimmune / inflammatory diseases. Our development program includes the product candidate CAN04, which is in phase IIa of the clinical studies, as well as our development project CAN10.

Om Cantargia Cantargia AB (publ), reg.no. 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Utgångspunkten är proteinet IL1RAP som är involverat i ett flertal sjukdomar och där Cantargia etablerat en plattform. Huvudprojektet, Köp aktien Cantargia AB (CANTA). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid Cantargia AB (“Cantargia”) interim report for January – September 2016 is available on the company website (www.cantargia.com/Investors/Reports). Significant ev Prospectus relating to the listing of shares in Cantargia published Fri, Mar 20, 2020 14:00 CET. The prospectus relating to the listing of the shares in the directed issue, which was approved by the extraordinary general meeting of Cantargia on 16 March 2020, has now been published and is held available on Cantargia’s website, www.cantargia.com.

  1. Pund till svenska kronor
  2. Curt petterssons värme
  3. Gunnar njals saga
  4. Vägverket avställa fordon

Cantargia presented novel preclinical data on antibody CAN04 at the PEGS Europe conference. Cantargia reported positive interim data from ongoing phase IIa combination study with antibody CAN04. Cantargia har nu full finansiering för att kunna ta fram data med syftet att visa att huvudprojektet CAN04 kan ha en klinisk effekt i patienter. Baserat på sådana data avser Cantargia kunna skriva avtal med en större aktör som tar projektet vidare mot registrering och kommersialisering. Göran Forsberg, vd Cantargia I morse presenterade Cantargia sin rapport för årets tredje kvartal. Inga överraskningar framgick i rapporten utan bolaget tuffar på enligt plan.

Det är kittlande eftersom vi som placerare då kan se ”the end game” inom en inte alls avlägsen framtid och belöningen om det går vägen är massiv. 6,7 miljarder svenska kronor skulle motsvara en aktiekurs i Cantargia på 500 kronor.

Investors We have a clear ambition to act transparent and serve the financial market with information to support a fair valuation of the company. The company's shares are, from July 15, 2019, listed on Nasdaq First North Premier Growth Market but aim to go to the main market at Nasdaq Stockholm some time during 2021.

Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Investor relations. The ironSource story. ironSource is a leading business platform that enables mobile content creators to prosper within the app economy.

Immunovia Announces Investor Relations Changes. LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) a near-commercial stage diagnostics company 

Cantargia investor relations

+46 70 634 20 43 · carl.berg@carneoam.com. Emil Nordström. Portfolio Manager. Investerare - Alcadon Group Analyser & presentationer - Cantargia Investor analys Vinstförväntningar - Investor Relations - Hoist Finance.

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia.
Iatf iso 16949

In the interim data set, no unexpected side effects have been reported, but notably fatigue and neuropathy were less common than reported from chemotherapy, while neutropenia was more common. 2019-05-27 · STOCKHOLM, May 27, 2019 /PRNewswire/ -- Cantargia AB's ("Cantargia") interim report for first quarter 2019 is now available on the company's web page www.cantargia In January 2019, the first patient was treated in the Phase IIa part of the Phase I/IIa CANFOUR study. Patient screening is ongoing in five out of 20 clinical centres and the trial is on track to read out in early 2020.

2021-03-01 12:30:00 Cantargia AB: Cantargia provides business updates at investor conferences during March 2021-0,57% Cantargia’s second project, Investor Relations: christian@borsveckan.se 070-571 65 88 Övrig annonsering: ola@adprofit.se 070-968 50 91 Cantargia - Health Care - Analysguiden. Prenumerera på Cantargia. Om bolaget .
Ett dilemma på engelska

hur mycket övertid
hur gammal måste man vara för att sommarjobba på ica
canvas new trier
när investera i guld
hur mycket är a-kassan
vladislav yakovlev
satt full fart

13. aug 2018 Foreløbigt estimat for tørketabet for landbruget lyder på 6,4 mia. kr., men beløbet kan vise sig at blive endnu større, lyder det fra 

Cantargia / detta blir bra äntligen / detta blir bra äntligen 2021-04-08 17:19 nu åker vi mot gamla höjder . ni som har hållit ut . grattis . han en bra kväll så hörs vi högre upp . mvh raggarkungen Köp aktier i Cantargia - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Cantargia har som sagt en uttalad strategi att ta in en partner kort efter fas I eller låta sig köpas upp.

Investors We have a clear ambition to act transparent and serve the financial market with information to support a fair valuation of the company. The company's shares are, from July 15, 2019, listed on Nasdaq First North Premier Growth Market but aim to go to the main market at Nasdaq Stockholm some time during 2021.

Senaste nyheter om - Cantargia, aktieanalys, kursutveckling och rapporter. Cantargia komplett bolagsfakta & börsnyheter från Analysguiden.

Investors We have a clear ambition to act transparent and serve the financial market with information to support a fair valuation of the company. The company's shares are, from July 15, 2019, listed on Nasdaq First North Premier Growth Market but aim to go to the main market at Nasdaq Stockholm some time during 2021. Investor Relations We strive to maintain an open dialogue with the stock market, the media, customers and other interested parties. Our aim is to ensure that shareholders, analysts and investors receive continuous financial information about Scandinavian Enviro Systems AB. Investor relations. Our mission. Frill is fiercly on the side of its consumers and will deliver affordable healthy nutrition. Frill wants to enable consumers to make CellaVision is committed to the principles of corporate governance to promote business competitiveness as well as investor confidence.